Program
blinatumomab
Also written as “Blinatumomab”, “MEDI-538” and “Blinatumomab (MT103)”.
Its studies are mostly in Precursor Cell Lymphoblastic Leukemia-Lymphoma · Lymphoma, Large B-Cell, Diffuse · Neoplasm, Residual · Lymphoma, Non-Hodgkin · Lymphoma, B-Cell, led by 4 companies.
Drug pageBlinatumomab: every studyAll 128 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Amgenits history only | 256 open or running | phase 4since Jul 27, 2020 | Jan 10, 2006 | Nov 24, 2027phase 2 · NCT04521231 |
| AstraZeneca | 20 open or running | phase 2since May 8, 2008 | Sep 28, 2007 | none ahead |
| Imugeneits history only | 10 open or running | phase 1since Sep 14, 2023 | Sep 14, 2023 | none ahead |
| Novartisits history only | 11 open or running | phase 2since Jan 13, 2026 | Jan 13, 2026 | Sep 19, 2033phase 2 · NCT07387926 |
Also a collaborator on its studies: BeOne Medicines, Merck and Amgen Astellas Biopharma.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of AstraZeneca only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 28, 2007First study: phase 1 study in Lymphoma, B-CellFirst studyNCT00538096 · 18 enrolled
- May 8, 2008Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT00676871 · 30 enrolled
TargetBeta
“T cell surface glycoprotein CD3 cross-linking agent; B-lymphocyte antigen CD19 cross-linking agent”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| surovatamig | AstraZeneca | phase 3 | 10 |
| Anti-CD19/CD3 Bispecific Antibody MK-1045 | Merck | phase 3 | 8 |
| YK012rule | excyte-biopharma-ltd | phase 2 | 5 |
| GSK5926371 | GlaxoSmithKline | phase 2 | 2 |
| Anti-CD19/CD3 T-cell Engaging Bispecific Antibody CLN-978rule | cullinan-therapeutics-inc | phase 1 | 4 |
| Anti-CD19/Anti-CD3/Anti-CD28 Trispecific Antibody CC312rule | cytocares-inc | phase 1 | 4 |
| Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565 | Novartis | phase 1 | 3 |
| ATG-201rule | antengene-biologics-limited | phase 1 | 1 |
| KT501rule | kali-therapeutics-inc | phase 1 | 1 |
| KT502rule | kali-therapeutics-inc | phase 1 | 1 |
Studies
All 2 AstraZeneca leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT00676871Leukemia, Lymphocytic, Chronic, B-Cell | 2 | Withdrawn | Mar 2010 | 30 |
| NCT00538096Lymphoma, B-Cell | 1 | Withdrawn | Mar 2010 | 18 |
How it is read
Names in the registry
- “Blinatumomab”, 25 entries
- “MEDI-538”, 10 entries
- “Blinatumomab (MT103)”, 2 entries
- “blinatumomab”, 1 entry
Conditions, from the studies’ own filings
- Precursor Cell Lymphoblastic Leukemia-Lymphoma, 13 studies
- Lymphoma, Large B-Cell, Diffuse, 4 studies
- Neoplasm, Residual, 2 studies
- Lymphoma, Non-Hodgkin, 2 studies
- Lymphoma, B-Cell, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.